Extracellular Vesicle Targeting for CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering modified extracellular vesicles (EVs) for therapeutic purposes face limitations in clinical efficacy due to lack of specificity and targeting capabilities, particularly for central nervous system (CNS) diseases, where traditional delivery methods fail to effectively reach target tissues.
Innovation Solution
The method involves compartmental administration of EVs equipped with biologically active molecules and exogenous targeting moieties, such as antibodies or peptides, to specifically target CNS tissues through routes like intrathecal, intraocular, or intracranial delivery, using anti-phagocytic signals like CD47 and tissue-specific ligands to enhance tropism and retention within the CNS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional delivery methods are used for EVs, then the delivery process is simple, but the EVs fail to reach target tissues effectively and lack specificity
Solution Approach 1:
The patent introduces targeting moieties (antibodies, peptides, ligands) as intermediary components that bridge EVs and target tissues. These moieties bind specifically to receptors on target cells, enabling precise delivery to desired tissues while leaving the EV delivery system itself relatively simple.
Solution Approach 2:
The patent applies local quality by equipping EVs with specific targeting moieties that are localized to their surface. This allows different regions of the EV system to have different functions: the EV core carries therapeutic cargo while the surface moieties provide targeted recognition and binding to specific tissue receptors.
2Reliability
If EVs are administered systemically, then distribution is broad, but retention in target CNS tissue is insufficient
Solution Approach 1:
The patent implements feedback mechanisms where targeting moieties on EV surfaces continuously recognize and bind to complementary receptors on target CNS cells. This binding feedback ensures EVs are retained at the target site, and unbound EVs can be recycled or redirected, reducing the total dosage needed.
Solution Approach 2:
The patent applies preliminary action by pre-equipping EVs with specific targeting moieties (such as antibodies against CNS-specific receptors) before administration. This pre-functionalization ensures that upon systemic administration, the EVs are immediately directed toward and retained in target CNS tissues rather than requiring high doses for statistical accumulation.
3Reliability
If EVs lack targeting moieties, then the EV structure is simple, but clinical efficacy is limited
Solution Approach 1:
The patent creates composite EV structures by combining the natural EV membrane with exogenously attached targeting moieties. This composite approach maintains the beneficial properties of natural EVs (biocompatibility, low immunogenicity) while adding targeted delivery capabilities through engineered surface components.
Solution Approach 2:
The patent applies universality by using a common EV platform that can be equipped with different targeting moieties for different diseases and tissue types. The same basic EV structure and methodology can be universally applied across various therapeutic applications by simply changing the targeting moiety, reducing overall engineering complexity through standardization.
Data Source
AI summary
The present disclosure relates compartmental administration of modified extracellular vesicles, e.g., exosomes. In some aspects, the extracellular vesicle, e.g., exosome, comprises a biologically active molecule and a targeting moiety.